Mechanistically, IL-17 activates STAT3, which provokes chronic inflammatory immune responses; hence IL-17 inhibition mediated by phosphorylated STAT3 can potentially reverse inflammation and IBD progression [36]. Here, IL17A is linked to inflammatory bowel disease.